Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul B Mullan

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Stem Cell Reviews and Reports|March 20, 2012
BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancerNiamh E Buckley, Paul B Mullan
Biochimica Et Biophysica Acta|August 22, 2006
BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?Paul B Mullan, Julia J Gorski, D Paul Harkin
World Journal of Clinical Oncology|December 14, 2020
Liquid biopsy in ovarian cancer: Catching the silent killer before it strikesLaura Feeney, Ian Jg Harley, W Glenn McCluggage, et al.
Therapeutic Advances in Medical Oncology|March 28, 2020
Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancerCatherine Knowlson, Paula Haddock, Victoria Bingham, et al.
The Oncologist|February 14, 2007
BRCA1, a potential predictive biomarker in the treatment of breast cancerColin R James, Jennifer E Quinn, Paul B Mullan, et al.
Journal of the National Cancer Institute|November 18, 2004
The role of BRCA1 in the cellular response to chemotherapyRichard D Kennedy, Jennifer E Quinn, Paul B Mullan, et al.
BMC Cancer|April 3, 2019
NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancerPaul B Mullan, Victoria Bingham, Paula Haddock, et al.
Oncotarget|August 4, 2016
Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs)Katy Orr, Niamh E Buckley, Paula Haddock, et al.
Cancer Research|October 16, 2003
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosisJennifer E Quinn, Richard D Kennedy, Paul B Mullan, et al.
Journal of Oncology|June 23, 2020
Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast CancerAhmed Elkashif, Victoria Bingham, Paula Haddock, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Stem Cell Reviews and Reports|March 20, 2012
BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancerNiamh E Buckley, Paul B Mullan
Biochimica Et Biophysica Acta|August 22, 2006
BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment?Paul B Mullan, Julia J Gorski, D Paul Harkin
World Journal of Clinical Oncology|December 14, 2020
Liquid biopsy in ovarian cancer: Catching the silent killer before it strikesLaura Feeney, Ian Jg Harley, W Glenn McCluggage, et al.
Therapeutic Advances in Medical Oncology|March 28, 2020
Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancerCatherine Knowlson, Paula Haddock, Victoria Bingham, et al.
The Oncologist|February 14, 2007
BRCA1, a potential predictive biomarker in the treatment of breast cancerColin R James, Jennifer E Quinn, Paul B Mullan, et al.
Journal of the National Cancer Institute|November 18, 2004
The role of BRCA1 in the cellular response to chemotherapyRichard D Kennedy, Jennifer E Quinn, Paul B Mullan, et al.
BMC Cancer|April 3, 2019
NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancerPaul B Mullan, Victoria Bingham, Paula Haddock, et al.
Oncotarget|August 4, 2016
Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs)Katy Orr, Niamh E Buckley, Paula Haddock, et al.
Cancer Research|October 16, 2003
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosisJennifer E Quinn, Richard D Kennedy, Paul B Mullan, et al.
Journal of Oncology|June 23, 2020
Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast CancerAhmed Elkashif, Victoria Bingham, Paula Haddock, et al.
Pageof 4